Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F de Clerck

Showing results (1-10 of 105) with videos related to

Pageof 11
Sort By:
Agents and Actions|August 1, 1986
Blood platelets in human essential hypertensionF De Clerck
Clinical Physiology and Biochemistry|January 1, 1990
The role of serotonin in thrombogenesisF De Clerck
Journal of Cardiovascular Pharmacology|January 1, 1991
Effects of serotonin on platelets and blood vesselsF De Clerck
The American Journal of Physiology|July 1, 1993
5-Hydroxytryptamine dominates over thromboxane A2 in reducing collateral blood flow by activated plateletsW Loots, F De Clerck
Angiology|July 1, 1981
Protection by flunarizine against endothelial cell injury in vivoJ Hladovec, F De Clerck
Agents and Actions|March 1, 1986
Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitroF De Clerck, B Xhonneux
European Journal of Pharmacology|April 10, 1990
Differential effects of nebivolol on adrenoceptors in the heart and in resistance arterioles in the rat. Quantitative intravital microscopic analysisW Loots, F De Clerck
Journal of Cardiovascular Pharmacology|January 1, 1985
Continuous inhibition of platelet S2-serotonergic receptors during chronic administration of ketanserin in humansF De Clerck, B Xhonneux
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 1, 1990
5-Hydroxytryptamine and thromboxane A2 in ischaemic heart diseaseF De Clerck, P A Janssen
Journal of Cardiovascular Pharmacology|July 1, 1993
R 56 865, a Na+/Ca(2+)-overload inhibitor, protects against aconitine-induced cardiac arrhythmias in vivoH R Lu, F De Clerck
Pageof 11

Showing results (1-10 of 105) with videos related to

Sort By:
Pageof 11
Agents and Actions|August 1, 1986
Blood platelets in human essential hypertensionF De Clerck
Clinical Physiology and Biochemistry|January 1, 1990
The role of serotonin in thrombogenesisF De Clerck
Journal of Cardiovascular Pharmacology|January 1, 1991
Effects of serotonin on platelets and blood vesselsF De Clerck
The American Journal of Physiology|July 1, 1993
5-Hydroxytryptamine dominates over thromboxane A2 in reducing collateral blood flow by activated plateletsW Loots, F De Clerck
Angiology|July 1, 1981
Protection by flunarizine against endothelial cell injury in vivoJ Hladovec, F De Clerck
Agents and Actions|March 1, 1986
Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitroF De Clerck, B Xhonneux
European Journal of Pharmacology|April 10, 1990
Differential effects of nebivolol on adrenoceptors in the heart and in resistance arterioles in the rat. Quantitative intravital microscopic analysisW Loots, F De Clerck
Journal of Cardiovascular Pharmacology|January 1, 1985
Continuous inhibition of platelet S2-serotonergic receptors during chronic administration of ketanserin in humansF De Clerck, B Xhonneux
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 1, 1990
5-Hydroxytryptamine and thromboxane A2 in ischaemic heart diseaseF De Clerck, P A Janssen
Journal of Cardiovascular Pharmacology|July 1, 1993
R 56 865, a Na+/Ca(2+)-overload inhibitor, protects against aconitine-induced cardiac arrhythmias in vivoH R Lu, F De Clerck
Pageof 11